| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 20.05. | Bristol Myers Squibb announces strategic agreement with Anthropic | ||
| 19.05. | ZPB Associates appoints Rachel Allan as Managing Director | ||
| 19.05. | LEO Pharma and Allergy UK launch 'Don't Ignore' chronic hand eczema campaign | ||
| 18.05. | GSK signs agreement with Protas to streamline clinical trials | ||
| 18.05. | Regeneron agrees research collaboration with Parabilis Medicines | ||
| 15.05. | AstronauTx appoints Michelle Mellion as Chief Medical Officer | ||
| 15.05. | US FDA approves Taiho's Inqovi for older adults with acute myeloid leukaemia | ||
| 14.05. | Lilly and UNICEF collaborate to improve non-communicable disease prevention | ||
| 14.05. | Zeno appoints Cendrine Seror as Head of Health, Europe | ||
| 13.05. | AbbVie Appoints Kelly Sanderson Schrems as UK VP and General Manager | ||
| 13.05. | Boehringer and Immunitas agree on licensing deal for chronic inflammatory and autoimmune diseases | ||
| 12.05. | Novartis breaks ground on US radioligand therapy site | ||
| 12.05. | OVID Health has appointed Davide Scalenghe as Head of Global Strategy & Partnerships | ||
| 11.05. | LEO Pharma to acquire Replay gene therapy platform | ||
| 11.05. | Cue Biopharma appoints Shao-Lee Lin as CEO, President and Director | ||
| 08.05. | Legend Biotech appoints new group of scientific advisors | ||
| 07.05. | Lilly commits additional $4.5bn for US manufacturing sites | ||
| 07.05. | Langland appoints Victoria Kent as Managing Partner, Medical Strategy & Education | ||
| 06.05. | FDA gives Rare Paediatric Disease designation to Satellite Bio for urea cycle disorders | ||
| 06.05. | GC Therapeutics appoints Stefan Irion as Chief Scientific Officer | ||
| 05.05. | adelo acquires Dot I/O Health, with Nigel Breakwell becoming Managing Partner | ||
| 05.05. | Innovative Trials appoints Anita Owen as first COO | ||
| 01.05. | UCB presentation highlights impacts of epilepsy on daily life | ||
| 01.05. | Inventiva appoints Axel-Sven Malkomes as Chief Financial Officer | ||
| 30.04. | Biogen agrees $850m felzartamab rights deal with TJ Biopharma |